Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Aug 11, 2026 to Jul 14, 2027
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Publications: details revised at 1 of 1 entry
  2. Study completion date: Sep 11, 2025 to Aug 11, 2026v27
  3. Study completion date: Dec 30, 2024 to Sep 11, 2025v26
  4. Study completion date: Dec 30, 2023 to Dec 30, 2024v25
  5. Study completion date: Sep 11, 2023 to Dec 30, 2023v24
Show 22 earlier versionsHide 22 earlier versions
  1. Results first posted: Apr 21, 2023
    • Primary endpoints: 4 to 2
    • Primary completion date changed from estimate of Sep 11, 2023 to Mar 6, 2022
    • Secondary endpoints: 1 to 2
    v23
  2. Primary and study completion dates: Sep 11, 2022 to Sep 11, 2023v22
  3. Primary and study completion dates: Aug 11, 2022 to Sep 11, 2022v21
  4. Primary and study completion dates: Jun 11, 2022 to Aug 11, 2022v20
  5. Primary and study completion dates: Jun 11, 2021 to Jun 11, 2022v19
  6. Primary and study completion dates: Jun 2020 to Jun 11, 2021
    • Start date: Jun 8, 2015 to Nov 11, 2015
    v18
  7. Primary and study completion dates: Jun 2019 to Jun 2020v17
  8. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v16
  9. Re-verified, no change to tracked fieldsv15
  10. Eligibility criteria expanded, about 4 wordsv14
  11. Primary and study completion dates: Jun 2018 to Jun 2019v13
  12. Eligibility criteria expanded, about 38 wordsv12
  13. Re-verified, no change to tracked fieldsv11
  14. Study completion date: Jun 2018
    • Start date: Jun 2015 to Jun 8, 2015
    v10
  15. Enrollment target: 10 to 20v9
  16. Re-verified, no change to tracked fieldsv8
  17. Eligibility criteria revised
    • Study description shortened, about 6 words
    v7
  18. Eligibility criteria shortened, about 56 wordsv6
  19. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Mar 2017 to Jun 2018
    • Start date: Sep 2015 to Jun 2015
    • Site details revised
    v5
  20. Start date: Mar 2015 to Sep 2015v4
  21. Site contact updatedv3
  22. Start date: Dec 2014 to Mar 2015
    • Primary completion date: Dec 2017 to Mar 2017
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
City of Hope Medical Center
411 trials monitored
See 53 trials at risk
Breast Cancer
5,455 trials monitored
See 306 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Colorectal Cancer
3,405 trials monitored
See 162 trials at risk
and 4 more diseases
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer. Diagnostic procedures, such as copper Cu 64 anti-CEA monoclonal antibody M5A PET, may help find and diagnose CEA positive cancer that may not be detected by standard diagnostic methods.
Trial Details
NCT Number NCT02293954
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastrointestinal Cancer, Liver and Intrahepatic Biliary Tract Cancer, Lung Cancer, Metastatic Cancer +4 more
Related terms Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Medullary, Colonic Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov